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State of the art
Mild cognitive impairment: historical
development and summary of research
James Golomb, MD; Alan Kluger, PhD; Steven H. Ferris, PhD

The conceptual development of MCI

F

amilies, caregivers, and physicians of persons with
Alzheimer’s disease (AD) generally find it difficult to
pinpoint, even in retrospect, the precise onset of a
patient’s cognitive impairment. The development of
dementia due to a degenerative neurological illness typically proceeds insidiously over several years from a
state of cognitive normalcy to progressively severe
stages of global intellectual dysfunction. While consensus criteria for diagnosing dementia and AD have been
published and widely adopted (Diagnostic and Statistical
Manual of Mental Disorders [DSM],1 National Institute
of Neurological and Communicative Diseases and
Stroke/Alzheimer’s Disease and Related Disorders
Association [NINCDS-ADRDA]2), guidelines for distinguishing between normal age-related cognitive
decline (ARCD) and the transitional levels of intellectual performance that precede the onset of dementia
have been slow to emerge. In fact, clinical investigators
have grappled with the problem of defining the boundaries of normal cognitive aging for over 40 years. In
1962, Kral3 coined the term “benign senescent forgetfulness” (BSF) to describe a population of nursing-

This review article broadly traces the historical development, diagnostic criteria, clinical and neuropathological
characteristics, and treatment strategies related to mild
cognitive impairment (MCI). The concept of MCI is considered in the context of other terms that have been
developed to characterize the elderly with varying
degrees of cognitive impairment. Criteria based on clinical global scale ratings, cognitive test performance, and
performance on other domains of functioning are discussed. Approaches employing clinical, neuropsychological, neuroimaging, biological, and molecular genetic
methodology used in the validation of MCI are considered, including results from cross-sectional, longitudinal,
and postmortem investigations. Results of recent drug
treatment studies of MCI and related methodological
issues are also addressed.
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Selected abbreviations and acronyms
AAMI
AD
ARCD
CDR
CIND
DAT
fMRI
GDS
MCI
MRS
PET
SPECT

age-associated memory impairment
Alzheimer’s disease
age-related cognitive decline
Clinical Dementia Rating
cognitive impairment–no dementia
dementia of the Alzheimer’s type
functional magnetic resonance imaging
Global Deterioration Scale
mild cognitive impairment
magnetic resonance spectroscopy
positron emission tomography
single photon emission computed tomography

home residents with mild memory deficits that were
anticipated to remain stable over time. Subsequently, this
concept has undergone many refinements resulting in a
proliferation of proposed entities including age-associated
memory impairment (AAMI),4 age-consistent memory
impairment (ACMI),5 late-life forgetfulness (LLF),5 and
ARCD.1 These constructs were intended to identify subjects whose cognitive performance had deteriorated
below values established for young adults, but were not
expected to undergo significant further decline and were
not believed to harbor neuropathological changes.
Nevertheless, a paucity of carefully collected follow-up
data makes it impossible to validate this hypothesis and
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Figure 1. Results of Medline searches for the number of citations detected
for the term “mild cognitive impairment” between 1989 and
2003. Separate searches were conducted for the term as a keyword and as a title.

it remains unclear whether meeting diagnostic criteria for
any of these syndromes really implies cognitive stability.
In contrast to these proposed definitions of “normal”
brain aging, Levy’s “aging-associated cognitive decline”
(AACD)6 included subjects who performed below normative levels for their own age-group making a pathological basis more likely.
In the 1980s, global clinical staging scales for the study of
AD were developed to more rigorously classify the
broad spectrum of intellectual performance found in
geriatric populations. Two of the most commonly used
scales, the Global Deterioration Scale (GDS)7 and the
Clinical Dementia Rating (CDR),8 both recognized the
need to categorize subjects without dementia who nevertheless exhibited some evidence for cognitive dysfunction. Subjects classified as GDS stage 3 or CDR stage 0.5
were considered cases of “questionable,” “borderline,” or
“preclinical” AD, whose cognitive status was intermediary between normal/AAMI/ARCD levels and mild
dementia. Other global dementia scales have defined
similar transitional stages, for example, “minimal dementia” from the Cambridge Mental Disorders of the Elderly
Examination (CAMDEX)9 and “limited cognitive disturbance” from the Comprehensive Assessment and
Referral Evaluation (CARE).10 Other constructs, such as
isolated memory loss,11 mild cognitive disorder,12 mild
neurocognitive disorder,1 and cognitive impairment–no
dementia (CIND),13-15 were intended to capture similar
levels of overall intellectual performance.
It was in this historical context that the expression “mild
cognitive impairment” gradually entered the lexicon of
the aging and dementia literature. In 1988, Reisberg et
al16 used it as a descriptive term coinciding with the GDS
stage 3. Three years later, the term appeared in the title
of an article by Flicker et al describing GDS stage 3 subjects at risk for dementia.17 In 1995, Petersen et al18 used
mild cognitive impairment (abbreviated as MCI) as an
independent diagnostic category not linked to a previously defined rating scale. In this case, the diagnosis was
applied to nondemented research subjects who retained
normal global cognitive function without impairment on
tasks of daily living, but had subjective memory complaints and scored below age-adjusted norms on memory
tests. Subsequent years have witnessed further elaboration, refinement, and redefinition of the concept with
interest growing markedly19 as exemplified by the exponential increase in published articles utilizing the term
(Figure 1).
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Criteria for diagnosis of MCI
While the notion of MCI as a transitional stage between
cognitive normalcy and dementia is easy enough to grasp,
it is presently unclear whether an operational definition
can be made sufficiently precise to define a unique and
useful diagnostic entity. Part of the difficulty lies in the
concept itself. Should MCI be construed as a syndrome
with multiple etiological explanations or should the concept be constrained to denote only patients with prodromal AD?20,21 Advocates of the former interpretation have
proposed a multitude of MCI subtypes corresponding to
the likely underlying neuropathological or psychiatric
diagnosis. For example, some proponents of this view
suggest vascular22 and frontotemporal23 subtypes of MCI.
Such a strategy, however, may open the door to an
unwieldy proliferation of subtypes that could weaken the
concept by excessively widening its scope (eg, hypothyroid MCI, brain tumor MCI, etc). It is therefore unclear
whether MCI should be considered the early stage of a
specific disease, a syndrome, or a syndrome constrained
by the exclusion of certain other diagnoses (Figure 2).24
The recognition that alternative neuropsychological presentations such as aphasia, ideomotor dyspraxia, or prominent behavioral and affective abnormalities may be relevant with respect to other neurodegenerative dementias
has prompted additional MCI subtypes based on the principal form of cognitive deficit present. For example,

Petersen22 has proposed a “multiple-domain MCI” for
patients exhibiting dysfunction across a range of neuropsychologic modalities, “single nonmemory cognitive
domain MCI” for patients whose cognitive symptoms
reflect circumscribed impairment in a nonmemory
domain, and “amnestic MCI” where memory loss is the
predominate reason for impairment. Amnestic MCI has
been proposed as the subtype most likely to portend a
diagnosis of AD. Because memory symptoms are salient
in most patients with early AD, this suggestion has certain
face validity. Nevertheless, neuropsychological studies
reveal that patients diagnosed with MCI have deficits in
several cognitive domains25-29 casting suspicion on whether
pure amnestic MCI, strictly speaking, actually exists. A
recent European Alzheimer’s Disease Consortium/
Alzheimer’s Disease Cooperative Study (EADC/ADCS)
consensus statement30,31 has expanded the initial concept
of amnestic MCI to allow for the presence of other nonmemory deficits (Figure 3). In addition to eliminating cases
that meet criteria for dementia, it has been suggested that
MCI ought not include patients with impairments in activities of daily living (ADL).22 The stipulation that ADL
impairment should be exclusionary, however, ignores the
commonly observed subtle difficulties with complex tasks
requiring organization and planning that MCI patients frequently experience.31 Thus, the EADC/ADCS revised criteria allow for mild decline in complex ADL.30,31 Requiring

Normal
cognition

Prodromal
dementia

Dementia

Brain aging

Reversible

To a large extent, this explosion of interest reflects a shift
of emphasis in dementia research away from established
disease and toward early diagnosis with the recognition
that effective therapy may be impossible once advanced
neurodegenerative pathology and tissue loss ensues.
Clearly, there are several conceptual advantages to the
establishment of MCI as a diagnostic category for patients
at risk for dementia. From the standpoint of clinical trials,
access to samples of nondemented patients likely to
undergo accelerated cognitive decline would greatly facilitate the testing of drugs aimed at arresting disease progression. Likewise, longitudinal studies designed to validate early biological or neuroimaging markers of AD
pathology also require access to at-risk populations.
Finally, the increase in public awareness of AD is driving
more patients with mild memory complaints to physicians,
who therefore need better diagnostic tools for estimating
prognosis.This need will become increasingly acute as the
population ages and as new treatments become available.

Mild cognitive
impairment

Other
dementias
Mixed

Stable or
reversible
impairment

Alzheimer's
disease

Vascular
dementia
Mixed

Figure 2. A conceptual model of mild cognitive impairment (MCI) as prodromal dementia. A minority of persons diagnosed with MCI
may remain stable or even improve over time. Although individuals with MCI may decline to vascular or other forms of
dementia, the majority of declining MCI patients evaluated in
research clinics receive a diagnosis of AD (either in pure form or
mixed with other dementia subtypes).
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Adapted from reference 24: Golomb J, Kluger A, Garrard P, Ferris S.
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Press; 2001. Copyright © 2001, Science Press.
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the presence of subjective memory complaints may also
be too restrictive. Many patients with borderline dementia deny symptoms of memory loss and impaired awareness of cognitive deficits has been recently described in
MCI.32 In practice, reports of impairment from family
members or other informants often substitute for subjective complaints by the patient.
Regardless of how these conceptual and taxonomic problems are resolved, the successful implementation of
MCI as a diagnostic category would seem to depend on
the development of a precise set of definitional rules.
Nevertheless, despite nearly 10 years of clinical research,
a single universally recognized standard has yet to
emerge. In general, the difficulty in formulating an operational definition for MCI reflects tension between precisely enumerated rules using cut-scores on staging instruments or psychometric tests and broader criteria that are
more conceptual in nature. The former strategy results in
a diagnosis that can be established more reliably, but may
be too narrow in scope and too complex for routine clinical purposes. The latter strategy, however, may allow too
much flexibility of interpretation and result in criteria that
are harder to implement consistently. Inevitably, a compromise solution will need to be reached, but some investigators may argue that existing constructs based on semistructured clinical interviews such as GDS stage 3 or
CDR stage 0.5 should form the main basis for diagnosis.
Despite the lack of universally accepted diagnostic crite"Amnestic" MCI
Memory
impairment
only

Memory plus
other domains
impaired

Alzheimer’s disease
major subtype
(Vascular dementia)

"Nonamnestic" MCI
Single
nonmemory
domain

Multiple
nonmemory
domains

Frontotemporal dementias
Lewy body dementia
Primary progressive aphasia
Parkinson’s disease
(Alzheimer’s disease)
(Vascular dementia)

Figure 3. European Alzheimer’s Disease Consortium (EADC)/Alzheimer’s
Disease Cooperative Study (ADCS) consensus on mild cognitive
impairment (MCI) subtypes.30 In this scheme, amnestic MCI consists of cases either with memory impairment alone, or accompanied with deficits in other cognitive areas. Similarly, nonamnestic MCI includes individuals with a deficit in a single
nonmemory domain and cases with impairment in multiple nonmemory domains.

ria, an increasing number of groups have been reporting
research on MCI populations defined using the classification schemes described above or variations of these
methods. The diagnosis is typically made when the clinical context, imaging data, and laboratory results exclude
structural, toxic/metabolic, ischemic, or primary psychiatric factors in favor of neurodegenerative processes as
the most likely causative mechanism. Regardless of the
specific criteria employed, clinicians with experience
diagnosing dementia are probably more in agreement
than not when characterizing such patients as nondemented, but cognitively impaired. It is therefore likely
that samples of MCI patients, particularly when defined
in dementia research centers, share enough attributes to
give the diagnosis overall “face validity.”

Prevalence of MCI
For a comprehensive treatment of epidemiological characteristics of MCI see the article by Ritchie in this issue.33 The
prevalence of MCI in older adults has been difficult to
determine. This is due, in part, to the lack of consensus on
diagnostic criteria for MCI that can be applied in epidemiological studies, the discrepancies in the age ranges examined, and the demographic characteristics of the samples
employed. Due to the protracted time course of MCI and
because the population of persons with dementia undergoes
an accelerated rate of attrition due to death, the prevalence
of persons with MCI at risk for AD is expected to outnumber cases actually diagnosed with AD.A review of population-based investigations of MCI prevalence has observed
widely varying rates across studies.34 An estimate of the
prevalence rate of MCI can be derived from data reported
on elderly from the Canadian Study of Health and Ageing.15
On the basis of pooled samples of community and institutional Canadian elderly aged 65 years and older, the estimated prevalence of CIND was 16.8%.This compared with
a prevalence of 8.0% for all types of dementia combined.
Since CIND is comprised of a number of categories, including circumscribed memory impairment, depression, drug
use, mental retardation, etc, it is likely that it is more inclusive than current definitions of MCI. The category of circumscribed memory impairment (the most frequent category of CIND) is probably less inclusive than current
definitions of MCI, and has a prevalence of 5.2%.Therefore,
the prevalence rate of MCI can be estimated to be between
5.2% and 16.8%.Yesavage et al35 have employed a Markov
model to estimate the most likely prevalence of MCI at spe-
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cific ages. MCI prevalence increased as a function of age:
1% at age 60; 6% at age 65; 12% at age 70; 20% at age 75;
30% at age 80; and 42% at age 85.

Validation of MCI
Establishing the validity of a clinically defined condition
such as MCI depends on it having properties that are distinct from those used to establish the diagnosis. Several
strategies have been used to validate the concept of MCI
including the following:
• Longitudinal studies demonstrating that MCI groups
are at increased risk for dementia.
• Cross-sectional studies demonstrating that MCI
patients exhibit psychometric, neuroimaging, and biomarker characteristics that are intermediary between
normal subjects and those with dementia.
• Neuropathological studies demonstrating that MCI
patients evidence either unique brain changes that would
justify a new diagnostic category, or brain changes consistent with an early stage of a dementing disorder.

of cholinesterase inhibitors and other potentially protective drugs. In the series reviewed by Bruscoli and
Lovestone,36 the single largest factor accounting for variability in decline was the source of the MCI subjects:
research clinic subjects had higher conversion rates than
community-living volunteers. The impact of subtle differences in definitional criteria on conversion rate is highlighted by a report by Morris et al,21 who subdivided
CDR=0.5 patients into three groups based on the CDR
subscale scores. These groups, defined as (i) uncertain
dementia of the Alzheimer type (DAT), (ii) incipient DAT,
and (iii) DAT, represented increasing degrees of clinical
confidence that prodromal AD was present. Results of survival analyses indicated that the 5-year rates of progression
to dementia (defined as a CDR≥1 at follow-up) were
19.9% for the uncertain DAT group, 35.7% for the incipient DAT group, and 60.5% for the DAT group. This compares with a 5-year rate of progression of 6.8% for controls
classified as having a CDR=0 at baseline.

Cross-sectional neuropsychological
differences in MCI

Longitudinal outcome in MCI
Several studies have examined rates of conversion to
dementia among clinical samples diagnosed with MCI.
Despite the use of different diagnostic criteria, these studies all demonstrate conversion rates that are higher than
the incidence of dementia in the general population, thus
lending overall validity to the notion that MCI patients are
at increased risk for significant cognitive decline. Bruscoli
and Lovestone36 identified 19 longitudinal studies published between 1991 and 2001 that reported conversion
rates from MCI to dementia.11,17,21,31,37-51 Although large differences in conversion were observed across these studies
(2% to 31%), the calculated mean annual conversion rate
was 10.24% (95% confidence interval [CI] 6.9%-11.9%).
This figure was slightly more than five times the mean incidence of dementia for similarly aged individuals (estimated to be 1.82%; 95% CI 1.38%-2.38%), based on
results from previously published reports.52,53
The highly disparate conversion rates across studies most
likely reflect several confounding factors including (i) differences in definitional criteria for MCI; (ii) cross-rater and
cross-center reliability differences in the implementation
of criteria for both MCI and dementia; (iii) differences in
study populations (eg, community versus research clinic);
(iv) differences in follow-up interval; and (v) variable use

For a thorough review neuropsychological methods used
in MCI see the article by Hahn-Barma et al in this issue.54
A number of studies have compared neuropsychological
test performance in subjects diagnosed as cognitively
normal, MCI, and AD. In general, MCI patients have
been found to perform more poorly than normal subjects
on a variety of tests that also separate mildly demented
patients from normal individuals. Results from several of
these studies are summarized in Table I.16,17,21,25,40,55-59
While mean neuropsychologic test score differences are
found to separate groups of normal, MCI, and mild
dementia subjects, significant overlap has been noted.25,55
These results highlight the inherent heterogeneity of
MCI as a diagnostic entity comprised of both patients
with early neurodegenerative disease and more benign
forms of ARCD. Interest has therefore focused on the
use of neuropsychological test instruments to predict longitudinal outcome in MCI.

Psychometric prediction of dementia in MCI
The following review is meant to be representative rather
than exhaustive, concentrating on studies that have
reported on the predictive accuracies of cognitive/psychometric instruments.A number of studies have assessed
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longitudinal decline in MCI groups. Rubin et al60 followed
16 individuals with MCI (CDR=0.5) over 7 years and
found that 69% had declined to dementia by the end of
the third year; no other cases converted beyond that time.
No formal neuropsychological test data were reported, but
the memory subscale of the CDR at baseline predicted
100% of the nondecliners and 64% of the decliners.
Similarly, Daly et al43 studied 123 MCI elderly over a
3-year interval and found that 18.7% declined to AD.The
sum of six subscales from the CDR (along with information from a clinical interview) correctly identified 90% of
the nondecliners and 83% of the decliners.
Flicker et al17 followed 32 normal (GDS=1-2) and 32 MCI
cases (GDS=3) over a 2-year follow-up interval and found
that 72% of the mildly impaired group progressed to a
dementia diagnosis. Classification analyses of the four cog-

nitive tests that showed poorer scores at baseline among
the decliners yielded high levels of specificity and sensitivity. These four tests assessed verbal recall, visuospatial
recall, and two aspects of language function. The verbal
recall test (learning a shopping list) was the best single predictor, correctly classifying 95% of the nondecliners and
90% of the decliners. Kluger et al48 studied 213 nondemented elderly (GDS=1-3) over an average follow-up
interval of 3.8 years. Of the 87 MCI (GDS=3) cases followed, 68% declined to dementia. Cut-scores from a paragraph delayed recall test assessing recent memory correctly identified 92% of the decliners and 79% of the
nondecliners, yielding an overall predictive accuracy of
87%.A diagnostically more restrictive subset of this MCI
sample (N=71) was also examined, of whom 66% declined
to a diagnosis of probable AD. This same paragraph cut-

Study

Setting/MCI definition

Reisberg et al,16
1988

Clinical research center
MCI (GDS=3)

60

44

Storandt and Hill,55
1989
Mitrushina et al,56
1989
Morris et al,57
1991

Clinical research center
Questionably demented (CDR=0.5)
Clinical research center
Outliers of well-functioning elderly
Clinical research center
Questionably demented (CDR=0.5)

83

41

19

19

4

10

Flicker et al,17 1991

Clinical research center
MCI (GDS=3)

32

32

Kluger et al,25 1997

Clinical research center
MCI (GDS=3)

41

25

234

76

177

227

107

769

Petersen et al,40 1999

Clinical research center
MCI (abnormal memory)
Morris et al,21 2001
Clinical research center
Three CDR=0.5 subgroups: DAT,
incipient DAT, and uncertain DAT
Grundman et al,58 2004 Multiple memory disorder centers
MCI: CDR=0.5 and objective
memory impairment

No. of subjects
Normal
MCI

Psychometric domains showing
decline in elderly patients with
MCI (versus normal controls)
Recent memory,
language/semantic memory,
attention, and psychomotor function
Recent memory, language, and
speeded psychometric function
Recent memory and language
Recent memory, language,
speeded psychometric function,
and comprehension
Recent and remote memory,
language, concept formation, and
psychomotor function
Recent memory, language, and
fine and complex motor/
psychomotor function
Recent memory and
language/semantic memory
Recent (episodic), semantic memory,
executive/psychomotor and visuospatial
function, and attention
Recent memory, language,
and psychomotor function

Table I. Studies examining cross-sectional psychometric differences between normal and mild cognitive impairment (MCI) elderly people. GDS, Global
Deterioration Scale; CDR, Clinical Dementia Rating; DAT, dementia of the Alzheimer’s type.
Updated from reference 59: Kluger A, Golomb J, Ferris SH. Mild cognitive impairment. In: Nawab Qizilbash, ed. Evidence-Based Dementia Practice. Oxford, UK:
Blackwell Science; 2002:341-354. Copyright © 2002, Blackwell Science.
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score correctly identified 96% of the decliners and 83% of
the nondecliners, providing an overall accuracy of 92%.
Similar findings have been reported by Tierney et al41 for
a cognitively diverse sample of research clinic–based, nondemented elderly individuals (GDS=2-3), by Devanand et
al38 for individuals with scores of CDR=0 to 0.5, as well as
by Masur et al28 for nondemented, healthy communityresiding elderly, who are likely to be comprised of both
normal and MCI individuals.
An overview of relatively large-sample longitudinal studies (N>70) that have reported predictive accuracies of
either individual or small sets of baseline neuropsychological test scores for predicting subsequent decline to
dementia is provided in Table II.28,38,41,44,48,59,61,62 These studies are organized according to the composition of the
nondemented samples at baseline: (i) primarily normal/AAMI/ARCD elderly; (ii) various combinations of
normal and MCI cases; or (iii) only MCI cases. One general pattern that emerges from this organizational
scheme is “the greater the proportion of MCI cases in the
nondemented sample, the greater the subsequent rates
of decline.” The reported predictive accuracies include
Study/nondemented sample

N

specificity versus sensitivity and/or negative predictive
value versus positive predictive value. The specificity of
a test signifies the percentage of all truly nondeclining
cases accurately classified by the predictor variable, while
the sensitivity indicates the percentage of all truly declining cases accurately classified by the predictor variable.
The negative predictive value denotes the percentage of
all cases classified by the predictor variable as nondeclining cases that actually do not decline, while the positive predictive value indicates the percentage of all cases
classified by the predictor variable as declining cases that
actually do decline. The overall accuracy identifies the
total percentage of subjects (true nondecliners plus true
decliners) accurately classified by the predictor variable.
The results of these studies assessing putative cognitive
predictors of dementia indicate that a small set of psychometric measures can relatively accurately detect
pathological decline in nondemented (especially MCI)
elderly people. The best single predictors were measures
of recent verbal/visuospatial learning and memory, especially from tests of delayed recall. Other predictors that
have been frequently identified include assessments of

Decline at
Specificity
follow-up (%)
(%)

• Samples containing normal elderly at baseline
Fuld et al,61 1990
474
11.8
84.0
Community-based study
Dal Forno et al,62 1995
196
12.2
–
Community-based study
• Samples containing various combinations of normal and MCI elderly at baseline
Masur et al,28 1994
317
20.2
94.0
Community-based study
Tierney et al,41 1996
123*
23.6
94.0
Memory-impaired sample
Devanand et al,38 1997
75
41.3
76.9
Memory-clinic–based study
Kluger et al,48 1999
213
34.7
92.8
Research-clinic–based study
179*
31.3
95.1
Grober et al,44 2000
264
12.1
80.0
Community-based study
• Samples containing MCI elderly at baseline
Kluger et al,48 1999
87
67.6
78.6
Research-clinic–based study
71*
66.2
83.3

Sensitivity
(%)

Predictive value (%)
Negative
Positive

57.0

89.0

39.0

–

91.0

62.0

50.0

88.1

68.1

76.0

–

–

81.0

83.3

73.9

72.9
87.5
85.0

86.6
94.4
-

84.4
89.1
-

91.5
95.7

81.5
90.9

90.0
91.8

Table II. Summary of relatively large-sample studies (N>70) examining the accuracy of neuropsychological measures in predicting decline to dementia.
MCI, mild cognitive impairment. *Decline to Alzheimer’s disease.
Reproduced from reference 59: Kluger A, Golomb J, Ferris SH. Mild cognitive impairment. In: Nawab Qizilbash, ed. Evidence-Based Dementia Practice. Oxford, UK:
Blackwell Science; 2002:341-354. Copyright © 2002, Blackwell Science.
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language function and psychomotor integration.
It is apparent that not all elderly who are classified as MCI
eventually decline to dementia, at least over follow-up
intervals of several years. If the definition of MCI at baseline is based on global staging scales (CDR=0.5 or
GDS=3), a trade-off can be observed between the added
strictness in the definition imposed by additional psychometric criteria and the proportion of decliners observed at
follow-up. But this added sensitivity comes at a cost: some
decliners will not be identified. Illustrating this point are
data described in Table III, representing a recalculation of
results from a previous longitudinal report.48 If MCI is
defined as all elderly with a baseline GDS=3 (a relatively
lax criterion), 68% (59 of 87 cases) of this group will decline
at follow-up, roughly 4 years later. If additional criteria are
imposed on top of the global scale scores (ie, progressively
poorer performance on a test of delayed paragraph recall),
the percentage of this group that will eventually decline
increases substantially. For example, if the definition of
MCI is based on GDS=3 as well as a recall score of ≤4 at
baseline, 98% (45 of 46 cases) of this group will decline, but
nearly one-quarter of the future decliners (14 of the 59
decliners) will be missed using this relatively strict definition. It is very likely that similar patterns of trade-offs will
occur with any sensitive psychometric, biological, or imaging marker when combined with a global scale score definition of MCI. For example, as has been seen, the stratification of the CDR stage 0.5 by the additional clinical
criteria suggested by Morris21 results in divergent expectations with respect to rapidity of decline to dementia.
Knowledge of these trade-offs has been helpful in selecting enriched MCI samples for drug-treatment trials.
Often, only those MCI cases (identified initially by global
rating scale classifications) with heightened risk of future
decline based on poor memory scores are included in the
treatment studies. The strictness of the criterion can be
adjusted, depending on the degree of risk associated with
the particular investigational compound.

Lax

Strict

MCI definition
GDS=3 and any recall score
GDS=3 and recall ≤ 10
GDS=3 and recall ≤8
GDS=3 and recall ≤6
GDS=3 and recall ≤4
GDS=3 and recall ≤2

Pathological basis of MCI
Most MCI patients identified in research clinics who
decline to dementia can be retrospectively diagnosed
with probable early stage AD. Such patients may therefore already harbor neuritic plaques and neurofibrillary
tangles (NFTs), the classically recognized histolopathological hallmarks of AD. In a large study of 109 community-dwelling older adults without dementia,63 33% were
found at autopsy to have neocortical neuritic plaques and
NFTs suggesting a pathological diagnosis of AD.
Methodological considerations preclude knowing how
many of these cases actually had MCI, but the findings
prompt speculation that gradations of AD-related
pathology could explain the milder degrees of intellectual dysfunction prevalent in nondemented populations.
The nature of the brain changes that distinguish pathological from normal aging and constitute the basis for
MCI are now becoming less obscure.
On the basis of a large autopsy series of 2661 cases,
Braak and Braak64 identified six age-associated stages of
neurofibrillary change where early NFT formation is
restricted to the entorhinal and transentorhinal regions
of the medial temporal lobe and occurs in the absence of
amyloid plaques. In autopsy studies of normal subjects
without any cognitive impairment (CDR=0), investigators have found NFTs to be ubiquitous, but generally
confined to the entorhinal cortex and hippocampus65 with
densities, particularly for the CA1 region, that increase
exponentially with advancing age.66 While most of these
cognitively normal cases had either no amyloid deposition or only diffuse nonfibrillar plaques, between 18%
and 45% may also exhibit neuritic plaques that are predominately concentrated in the limbic regions of the
medial temporal lobe.65-67 It is therefore apparent that
some cognitively normal subjects harbor “preclinical”
brain changes consistent with a pathological diagnosis of
early AD; presumably, such individuals will eventually

Decline to dementia (%) (N1/N2)
68 (59/87)
73 (58/79)
81 (56/69)
90 (54/60)
98 (45/46)
100 (34/34)

Declining cases missed (%) (N/59)
0 (0/59)
2 (1/59)
5 (3/59)
8 (5/59)
24 (14/59)
42 (25/59)

Table III. Trade-off between strictness of mild cognitive impairment (MCI) criterion (based on New York University [NYU] delayed paragraph recall) and
decliners missed. GDS, Global Deterioration Score. Recalculated from data in Kluger et al.48
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magnetic resonance imaging (MRI) studies conducted on
postmortem brains have shown hippocampal volume
reductions that correlate with the Braak stage of neurofibrillary degeneration.78,79 In vivo studies confirm that hippocampal atrophy is a frequent characteristic of MCI80-83
and can predict the occurrence of subsequent dementia.46,84,85 Hippocampal atrophy has also been demonstrated
in nondemented subjects destined to develop AD due to
the amyloid precursor protein (APP) 717Val-Gly mutation.86 Up to one-third of highly functioning cognitively
normal older adults exhibit milder degrees of hippocampal atrophy that correlate with diminished delayed recall
performance.87,88 Hippocampal volume loss in these cases
may not always reflect the presence of AD pathology,74 but
might correspond to benign age-associated neurofibrillary
changes. More recent MRI studies have found atrophy of
the entorhinal cortex in MCI patients89-91 with greater volume reductions in cases that decline to dementia.92
Nevertheless, it is unknown whether entorhinal atrophy
precedes hippocampal atrophy during the pathogenesis of
AD or whether MRI measurements of the entorhinal cortex correlate better than volume measurements of the hippocampus with a diagnosis of MCI.93 It is likewise unclear
if either measure is a better predictor of risk for subsequent decline.88,91

Normal cognition

Cognitive decline

develop MCI and dementia upon longitudinal observation. Virtually all CDR=0.5 (MCI) subjects studied by
Price and Morris were found to have neuritic plaques distributed more diffusely, involving neocortical as well as
limbic regions.21,66 These data indicate that MCI, defined
as CDR=0.5, may represent early AD more often than
previously believed. Such observations, however, must be
reconciled with the widely disparate rates of longitudinal
decline exhibited by MCI subjects. As discussed previously, the etiological heterogeneity of MCI is most likely
influenced by clinical diagnostic criteria as well as the
characteristics of the population sampled.
Current research therefore supports the view that a slow
progressive increase in medial temporal (entorhinal,
perirhinal, and hippocampal) neurofibrillary pathology is
the histopathological signature of normal brain aging and
generally occurs with minimal or no cognitive consequences. These changes may, however, underlie the more
subtle and benign memory deficits observed in normal
aging and could represent the pathologic basis for
AAMI/ARCD. The emergence of neuritic plaques within
the medial temporal lobe and neocortex, however, may be
the pathological substrate of MCI and signal the onset of
AD (Figure 4). Why some persons with medial temporal
AD pathology are unimpaired (CDR=0), while others
exhibit MCI is at present uncertain, although the explanation may, in part, reflect the emergence of neuronal loss
within the entorhinal cortex,68,69 a more widespread neocortical localization of plaques and tangles,66 and, perhaps,
changes in synaptic morphology and density.70 Although
they are less pronounced, neurofibrillary changes also
affect the nucleus basalis of Meynert in aging and become
more pronounced with MCI.71 While cholinergic deficiency
could therefore also account for the symptoms of MCI, this
has been called into question due to the lack of associated
reductions in cortical choline acetyltransferase activity.72

AAMI/ARCD

NFTs in entorhinal corte

x and hippocampus

NFTs and neuritic plaques in
medial temporal lobe

MC

I

NFTs and neuritic plaques in
association cortex

AD

Time (years)

Neuroimaging findings in MCI
Structural imaging
Given the clinical and pathological results described
above, it is understandable that neuroimaging research in
MCI has focused on the medial temporal lobe, with particular emphasis on such structures as the hippocampus
and entorhinal cortex.The accumulation of AD pathology
affecting this anatomy is reflected in volume loss73 and,
although hippocampal atrophy is not specific to AD,74-77

Figure 4. Schematic representation of the distinction between normal
(upper curve) and pathologic (lower curve) brain aging. This
view, supported by recent clinical pathological studies, suggests
that minimal cognitive decline is associated with an age-dependent accumulation of medial temporal lobe neurofibrillary
change. The emergence of mild cognitive impairment (MCI) is
preceded by the appearance of neuritic plaques as well as neurofibrillary degeneration, both of which become more concentrated and widely distributed with the progression of cognitive
symptoms. AAMI, age-associated memory impairment; ARCD,
age-related cognitive decline; AD, Alzheimer’s disease; NFT, neurofibrillary tangle.
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Structural MRI studies have begun to examine medial
temporal lobe volumes as predictors of MCI. An earlier
study of highly functioning cognitively normal subjects
found baseline measurements of hippocampal size to predict subsequent changes in memory performance and the
development of MCI.94 More contemporary studies have
analyzed scans at two or more time points to calculate volumetric rates of change.95-98 These studies confirm that
higher rates of atrophy affecting medial temporal lobe
structures can predict longitudinal cognitive decline and
the emergence of MCI. Such results also highlight the
potential for using structural MRI as outcome measures
in pharmacological trials targeting MCI subjects. At present, however, it is uncertain whether neuropsychological
decline can be more robustly detected over a shorter time
interval than structural radiographical change.
Functional imaging
Functional imaging research in MCI has included studies using positron emission tomography (PET), single
photon emission computed tomography (SPECT), functional magnetic resonance imaging (fMRI), and magnetic
resonance spectroscopy (MRS).
Positron emission tomography
PET studies using the radiotracer 2-deoxy-2[18F]fluoroD-glucose (18FDG) have been employed for over 20 years
to study regional rates of glucose utilization in the brain.
AD patients tend to exhibit characteristic metabolic
reductions in the temporal and parietal association cortices99-101; a distribution that coincides with the neuropathological distribution of AD pathology. FDG studies in patients with MCI have demonstrated similar
topographic patterns, as well as metabolic reductions in
the posterior cingulate gyrus.102-106 Subjects at high genetic
risk for AD (due to apolipoprotein E4 [ApoE-4]
homozygocity) also exhibit glucose utilization reductions
in regions similar to those that become involved in AD.107
Evidence is conflicting concerning the presence of metabolic reductions within the medial temporal anatomy
affected in early AD. Some groups have not found differences,108 while others have reported decreased glucose
utilization rates affecting the hippocampus and other limbic structures including the mammilary bodies, amygdala,
and medial thalamus.109,110 One study found metabolic
reductions within the entorhinal cortex to be associated

with longitudinal decline to MCI and AD.111 These studies, however, draw their conclusions from small samples
and purport to measure structures that challenge the spatial resolving power of the equipment. Despite statistical
adjustments for atrophy, it seems possible that tissue loss
may be confounding these results, particularly given the
findings from numerous structural imaging studies
reviewed previously. Cerebral perfusion imaging using
SPECT may also be useful in predicting subsequent
dementia among patients with MCI.112,113
Functional magnetic resonance imaging
Brain activity following a stimulus can be localized with
fMRI, a technique that is sensitive to the small changes
in blood oxygenation associated with increased regional
metabolic demand. Using visual memory tests to activate
the medial temporal lobe, MCI subjects were found to
exhibit a smaller fMRI response than cognitively normal
subjects, though differences between MCI and AD were
not detected.114 Another fMRI study found poor activation within the hippocampus in all MCI subjects, while
some had normal entorhinal cortex responses suggesting
anatomical heterogeneity with respect to memory processing.115 A recent MCI study116 found that visual memory test performance correlated with medial temporal
lobe activation but, surprisingly, activation was more
extensive in patients who developed dementia compared
with those who remained stable. Like PET and structural
MRI studies, nondemented patients at high genetic risk
for dementia may exhibit decreased patterns of brain
activation compared with controls.117
Magnetic resonance spectroscopy
Using proton MRS (1H-MRS), several groups have found
brain metabolite concentrations for N-acetylaspartate
(NAA) and myoinositol (MI) to distinguish AD patients
from controls although conflicting results have been
reported for choline.118 Decreased NAA concentration
relative to creatine (NAA/Cr) is considered to be an
MRS marker of diminished neuronal density and viability. Elevations in MI/Cr ratios are less specific, but may be
associated with glial activation and other neurochemical
processes; it is unclear how this may relate to AD pathogenesis. Compared with normal controls, some investigators have found increased MI/Cr in the posterior cingulate gyrus and white matter of MCI patients.119,120
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Nondemented Down’s syndrome patients at high risk for
AD also have elevated MI/Cr ratios.121 A recent study
observed that decreased medial temporal lobe NAA/H2O
ratios distinguished MCI patients from normal controls,
while increased parietotemporal MI/H2O distinguished
MCI cases from AD.122 Further research will determine
whether MRS can identify a specific metabolite signature
that differentiates early AD pathology. Some evidence,
however, suggests that while NAA/Cr may be a nonspecific marker for age-related neuronal dysfunction and
cognitive decline, MI elevations may be a better index of
neuropathology.123
Imaging AD pathology
Recently developed amyloid imaging tracers for PET have
resulted in pilot studies with promising initial findings.124,125
The positron-emitting [11C]benzothiazole derivative known
as Pittsburgh compound-B (PIB) has been shown to effectively discriminate a group of 16 mild AD patients from
cognitively normal controls in a recently published PET
study.124 The absence of PIB retention within white matter
or cerebellar regions (the latter an area of nonfibrillar
β-amyloid [Aβ] accumulation) suggests that this agent may
specifically image the neuritic plaque deposits that characterize early AD.Although MCI cases were not included,
7 patients were very mildly impaired, as evidenced by
Mini-Mental State Examination (MMSE) scores ≥ 27.The
patterns of PIB uptake for 3 of these mildly impaired
cases were indistinguishable from control values casting
some early doubt on the sensitivity of this technique for
identifying MCI cases with AD pathology. Further
research will undoubtedly clarify the potential of PIB and
other amyloid imaging techniques for making an early
diagnosis of AD and monitoring progression of pathology
over time.

Biological markers of AD pathology in MCI
Over the past decade, several groups have compared
cerebral spinal fluid (CSF) from AD patients with fluid
from cognitively normal controls in an effort to identify
biological markers indicative of AD pathology. Although
a large number of candidate markers have been examined, recent interest has focused on observations that
CSF concentrations of tau, a microtubule-associated protein comprising NFTs, is elevated in AD,126,127 while levels
of the 42 residue form of the Aβ peptide (Aβ1-42) are

decreased.128 As reviewed in this issue by Hampel and
Blennow,129 multiple studies over recent years have confirmed that these biomarkers can effectively discriminate
control subjects from demented patients with a clinical
diagnosis of AD. Averaging across 43 studies while fixing
diagnostic specificity at 90%, these authors130 found mean
sensitivities of over 80% for CSF measurements of total
tau and Aβ1-42. Overall discrimination may be somewhat
improved by detecting the abnormally phosphorylated
forms of tau (phospho-tau) that occur in neurons undergoing neurofibrillary degeneration in AD.131,132 Nearly all
groups who have studied CSF tau and Aβ1-42 in MCI
populations have found mean concentrations to be intermediary between AD and control values, but closer to
the AD levels in patients who decline to dementia.133-138
These results highlight the biological heterogeneity of
MCI and suggest that phospho-tau measurements, in particular, could be useful in identifying cases of prodromal
AD. As a potential index of AD pathological burden, tau
and Aβ1-42 concentrations could be useful outcome measures in treatment studies. Some preliminary evidence,
however, suggests that repeated measurements may not
always correlate with disease progression.136 It also
remains to be determined whether these CSF markers
are better predictors of cognitive decline than the structural and functional imaging techniques reviewed previously. Clearly, longitudinal studies in MCI using combinations of brain imaging, psychometric testing, and CSF
sampling need to be performed before these questions
can be addressed.

Genetic markers of AD pathology in MCI
It is now well recognized that persons carrying the ε4 isoform of ApoE are at increased risk for developing lateonset AD.139 While overexpression of the ε4 allele might be
expected in MCI compared with normal controls, its frequency would not be likely to reach the levels seen in AD,
since MCI cases comprise not only preclinical AD, but also
other more benign conditions predisposing to cognitive
impairment. In one large study, the prevalence of nondemented persons with at least one copy of the ε4 allele
was 22%, while in AD the frequency was 64%.140 Values
intermediary between these estimates were found in several studies of nondemented memory impaired individuals who appear to satisfy criteria for the diagnosis of
MCI.14,18,141,142 Two large population-based studies found that
ε4 status was a significant risk factor for MCI.143,144
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Most studies have found ε4 to exert a cognitive impact on
nondemented older adults. In community samples of nondemented elderly, although one cross-sectional study did
not find a significant relationship between ε4 status and
cognition,145 other longitudinal studies found ε4 to be a
predictor of accelerated cognitive decline.146-148 According
to one report,149 nondemented subjects who carried an
ε4 allele were more likely to have subjective memory
complaints than those without ε4. In studies of cognitively
normal persons with high MMSE scores, the impact of
age on memory performance (and memory change over
time) was more pronounced in ε4 homozygotes relative
to those without ε4.150-152 These latter reports indicate that
ε4 may subtly influence cognitive performance even
before the onset of MCI; it is unknown whether this influence can precede the emergence of AD pathology.
Although epidemiological and longitudinal clinical data
support ε4 as a risk factor for dementia and cognitive
decline, its utility as a predictor of clinical outcome in
MCI populations needs to be compared with imaging,
biomarker, and neuropsychological variables.

Treatment of MCI
The treatment of MCI is reviewed in detail by Gauthier
later in this issue.153 Currently, there are no pharmacological treatments for MCI with proven efficacy or regulatory approval. However, clinically there appears to be
growing use in MCI of the marketed AD treatments,
donepezil, rivastigmine, galantamine, and memantine. A
number of clinical trials in MCI patients have been conducted, thus far with mixed results. For example, a 6month, placebo-controlled trial of donepezil failed to
show significant efficacy on the primary end points, but
did show efficacy on some secondary cognitive measures.154
Since a high proportion of “amnestic” MCI patients (presumably representing cases of prodromal AD) progress
to an AD diagnosis within several years, 2- to 4-year “survival” clinical trial designs have been conducted with
MCI patients in which “conversion” to AD is the primary
outcome. Such studies are used to determine if a treatment can slow the progression of symptoms. For example, a 3-year trial of vitamin E, donepezil, or placebo
failed to show an effect on conversion of vitamin E, but
did demonstrate a benefit of donepezil at 6, 12, and 18
months.155 Since there was no benefit at 2 to 3 years, these
results for donepezil are consistent with a symptomatic

effect that lasts for up to 18 months. A similar 2-year trial
of galantamine in MCI failed to show a benefit on the
primary end points, but there was some benefit on a secondary cognitive measure.156 Results of a 3- to 4-year conversion trial of rivastigmine have not as yet been
reported, but a similar 4-year trial of the anti-inflammatory drug rofecoxib failed to show any clinical efficacy.157
Despite the mixed and generally disappointing results of
these initial MCI clinical trials, an important general finding is that when the patients progressed to dementia over
the course of the trial, the specific diagnosis was almost
always AD. This result provides some validation for the
operational criteria used to select cases with “amnestic/AD type” MCI.

Conclusion
The concept of MCI in the elderly has evolved over the
past 40 years to the point where study of MCI is at the
cutting edge of research on the early pathology, early
diagnosis, and early treatment of AD. The broad syndrome of MCI, defined clinically as a state of mild
impairment that is intermediate between the decline
associated with brain aging and the clear deficits that
occur in dementia, is clearly heterogeneous with respect
to outcome and underlying etiology. However, it is apparent that the major MCI subgroup consists of individuals
destined to progress to a diagnosis of AD. As reviewed
above, this conclusion is supported by growing number
of cross-sectional and longitudinal studies, as well as by
studies examining postmortem neuropathology and in
vivo neuroimaging and biomarker correlates of AD.
Furthermore, since it is feasible clinically to operationalize the identification “amnestic” MCI cases who are
likely to have very early AD, such individuals have
become an important research group for inclusion in clinical trials designed to examine agents that may slow the
progression of AD.
Although clearly valuable as a research tool, it may be
debated whether physicians in clinical practice should
consider a diagnosis of MCI for individual patients.
Because MCI is a heterogeneous entity comprising a
variety of neuropathological and psychiatric disorders,
and because dementia is not an inevitable outcome, the
term may carry too little prognostic and diagnostic
weight to legitimize its widespread use on a case-by-case
basis. Furthermore, the lack of universally agreed upon
criteria and the public’s unfamiliarity with the concept
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could result in increasing uncertainty, anxiety, and misunderstanding. Rather than invoking MCI, patients might
be better served if their physicians simply conveyed an
opinion regarding the most likely underlying pathological mechanism. For example, a patient with progressive
memory loss and poor neuropsychological test performance might be told that early AD pathology is likely,
while a patient with minimal objective memory impairment could be informed that such an explanation is less
plausible. If medical, neurological, or brain imaging evidence supports other etiologically relevant conditions,
this too could be imparted to patients as alternative or
contributing factors. It might therefore be asked whether

any additional information is gained by adding MCI to
the diagnosis. On the other hand, patients and families
might be comforted by the MCI label, provided that it is
properly explained as a “risk” condition, rather than as a
definitive diagnosis of “early AD.” Regardless of the
unresolved issues and possibly premature nature of MCI
as a psychiatric or neurological “diagnosis” in a patient
care setting, the MCI concept has had, and will continue
to have, great relevance and importance to research on
the causes, early diagnosis, and early treatment of AD. ❏
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Deterioro cognitivo leve: desarrollo histórico
y resumen de investigaciones

Déficit cognitif léger : développement
historique et résumé de la recherche

Este artículo de revisión investiga de manera general el desarrollo histórico, los criterios diagnósticos,
las características clínicas y neuropatológicas, y las
estrategias terapéuticas que se relacionan con el
deterioro cognitivo leve (DCL). El concepto de DCL
se incluye dentro del contexto de otros términos
que han sido desarrollados para caracterizar la
vejez con grados variables de deterioro cognitivo.
Se discuten los criterios basados en evaluaciones de
escalas clínicas globales, rendimiento en pruebas
cognitivas y rendimiento en otros dominios del funcionamiento. También se revisan aproximaciones
que utilizan metodología clínica, neuropsicológica,
de neuroimágenes, biológicas y de genética molecular empleadas en la validación del DCL, incluyendo resultados de investigaciones transversales,
longitudinales y postmortem. Además se consignan resultados recientes de estudios farmacológicos en el DCL y temas metodológicos afines.

Cet article retrace à grands traits le développement
historique, les critères diagnostiques, les caractéristiques cliniques et neuropathologiques ainsi que les
stratégies du traitement du déficit cognitif léger
(mild cognitive impairment, MCI). Le concept de MCI
est étudié conjointement avec d’autres termes créés
pour qualifier les personnes âgées présentant des
degrés variables de déficit cognitif. Les critères basés
sur des échelles de comportement clinique global, les
résultats de tests cognitifs et des bilans relatifs à
d’autres domaines fonctionnels sont également passés en revue. Nous abordons les méthodes cliniques,
neuropsychologiques, de neuro-imagerie, biologiques et de génétique moléculaire utilisées pour confirmer le MCI, y compris les résultats issus d’études
transversales, longitudinales et post-mortem. Nous
présentons également les résultats d’études sur de
nouveaux médicaments pour traiter le MCI et les
questions méthodologiques qui s’y rattachent.
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